Paclitaxel for Bladder Cancer
Author Information
Author(s): D Papamichael, CJ Gallagher, RTD Oliver, PW Johnson, J Waxman
Primary Institution: St Bartholomew's Hospital
Hypothesis
Can paclitaxel be effective in patients with previously treated locally advanced/metastatic transitional cell carcinoma of the bladder or ureter?
Conclusion
Paclitaxel showed low efficacy in treating relapsed patients with advanced bladder cancer, with only one patient responding.
Supporting Evidence
- One patient achieved a partial response lasting 7.4 months.
- Three patients experienced stable disease for 54-164 days.
- Severe haematological toxicity was observed in 23 out of 42 treatment courses.
Takeaway
Doctors tested a medicine called paclitaxel on 14 patients with advanced bladder cancer, but it didn't work very well.
Methodology
Patients received paclitaxel at a dose of 200 mg/m² every 21 days, and their responses were assessed every two cycles.
Limitations
The study involved a small number of patients and focused on a group with poor prognosis.
Participant Demographics
Patients were aged 40-73, with a median age of 68, and included 9 males and 5 females.
Statistical Information
Confidence Interval
95% CI 2-12%
Want to read the original?
Access the complete publication on the publisher's website